Close Menu

NEW YORK – Precision oncology biotech Black Diamond Therapeutics recently began enrolling patients with EGFR- and HER-mutated cancers into a tissue agnostic Phase I/II trial for its lead product, BDTX-189.

The Cambridge, Massachusetts-based company, which debuted on the stock market last month with an initial public offering that brought in $200 million, was founded in 2014 by CEO David Epstein and Elizabeth Buck with the goal of developing therapies for patients with molecularly-defined cancers who lack treatment options.

Get the full story with
Premium Access

Only $95 for the
first 90 days*

Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try Premium Access now.

You may already have institutional access!

Check if I qualify.

Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.